| Not Yet Recruiting | AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculos NCT07467252 | Ministry of Health, Saudi Arabia | Phase 2 |
| Not Yet Recruiting | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese C NCT07268664 | Beijing Chest Hospital | Phase 3 |
| Recruiting | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis NCT07209761 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Not Yet Recruiting | Ultra-Short Regimen for Elderly DS-TB NCT07076225 | Shenzhen Third People's Hospital | Phase 3 |
| Recruiting | A PAN-USR TB Multi-Center Trial NCT06905522 | Shenzhen Third People's Hospital | Phase 3 |
| Not Yet Recruiting | Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study NCT06922916 | Zhejiang University | — |
| Recruiting | Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis NCT06192160 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Active Not Recruiting | I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis NCT07186478 | Hasanuddin University | N/A |
| Active Not Recruiting | Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese C NCT06649721 | Huashan Hospital | Phase 3 |
| Recruiting | Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Bre NCT06528418 | ChromX Health | — |
| Recruiting | The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary I NCT06476210 | Beijing Chest Hospital | Phase 4 |
| Recruiting | Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB NCT06114628 | University College, London | Phase 2 |
| Recruiting | ATORvastatin in Pulmonary TUBerculosis NCT06199921 | Obafemi Awolowo University Teaching Hospital | Phase 2 |
| Recruiting | Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial NCT06727864 | Kaohsiung Veterans General Hospital. | Phase 3 |
| Active Not Recruiting | Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosi NCT06081361 | Beijing Chest Hospital | Phase 3 |
| Recruiting | Rehabilitation of People With Post-tuberculosis Lung Disease NCT06127641 | Centro Universitário Augusto Motta | N/A |
| Active Not Recruiting | Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pu NCT06058299 | Global Alliance for TB Drug Development | Phase 2 |
| Terminated | Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PB NCT05971602 | Gates Medical Research Institute | Phase 2 |
| Recruiting | PanACEA - STEP2C -01 NCT05807399 | Michael Hoelscher | Phase 2 |
| Unknown | Epidemiological Study of Hospitalized Children for Pulmonary Tuberculosis at Strasbourg University Hospitals NCT06110533 | University Hospital, Strasbourg, France | — |
| Unknown | Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculos NCT05359315 | SPP Pharmaclon Ltd. | — |
| Unknown | Study on Three Doses of an Inactivated COVID-19 Vaccine in Chinese Pulmonary Tuberculosis Patients NCT05148949 | Jiangsu Province Centers for Disease Control and Prevention | Phase 4 |
| Completed | PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) NCT04550832 | LigaChem Biosciences, Inc. | Phase 2 |
| Unknown | Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect NCT05046366 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Completed | Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) NCT04930744 | University of Massachusetts, Worcester | Phase 2 |
| Completed | Prokinetic Effect of Selected Nutraceuticals NCT06157034 | Allama Iqbal Open University Islamabad | N/A |
| Completed | Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From Wearable Devices in Respiratory Dise NCT04857814 | University of Alberta | N/A |
| Completed | PanACEA Sutezolid Dose-finding and Combination Evaluation NCT03959566 | Michael Hoelscher | Phase 2 |
| Recruiting | Novel Triple-dose Tuberculosis Retreatment Regimen NCT04260477 | Institute of Tropical Medicine, Belgium | Phase 3 |
| Completed | Diagnostic Accuracy of CAD4TB and C-reactive Protein Assay as Triage Tests for Pulmonary Tuberculosis NCT04666311 | Klaus Reither | — |
| Completed | Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 NCT04608955 | Shanghai Jiatan Pharmatech Co., Ltd | Phase 2 |
| Unknown | Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct NCT04504851 | National University Hospital, Singapore | Phase 2 |
| Unknown | Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PT NCT04187469 | Fifth Affiliated Hospital, Sun Yat-Sen University | N/A |
| Completed | StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberc NCT03882177 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis NCT04176250 | Gates Medical Research Institute | Phase 2 |
| Unknown | A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut Universit NCT04055441 | Assiut University | — |
| Unknown | PRACTECAL-PKPD Sub Study NCT04081077 | Medecins Sans Frontieres, Netherlands | Phase 2 / Phase 3 |
| Completed | Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in P NCT02381470 | National University Hospital, Singapore | Phase 2 |
| Unknown | Tuberculosis Cohort in the North of Paris NCT04236349 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis NCT05896930 | TASK Applied Science | Phase 2 |
| Withdrawn | Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz NCT03277742 | Instituto Nacional de Salud Publica, Mexico | N/A |
| Completed | Using Biomarkers to Predict TB Treatment Duration NCT02821832 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosi NCT02581527 | St George's, University of London | Phase 3 |
| Completed | A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK NCT02836483 | LigaChem Biosciences, Inc. | Phase 2 |
| Completed | Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae NCT02736864 | Federal University of Uberlandia | — |
| Completed | Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB NCT03350048 | Prof Gerhard Walzl | — |
| Completed | Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion NCT02465216 | Access to Advanced Health Institute (AAHI) | Phase 2 |
| Completed | Assessing PA-824 for Tuberculosis (the APT Trial) NCT02256696 | Johns Hopkins University | Phase 2 |
| Completed | A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB NCT02333799 | Global Alliance for TB Drug Development | Phase 3 |
| Completed | NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis NCT02371681 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis NCT02169570 | Dow University of Health Sciences | Phase 4 |
| Completed | A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) NCT02279875 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Prospective Assessment of TBDx Feasibility NCT02912832 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Completed | Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycill NCT02349841 | TASK Applied Science | Phase 2 |
| Completed | Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy? NCT02331056 | Samsung Medical Center | — |
| Completed | Pulmonary Tuberculosis Patients With Diabetes Mellitus NCT02106039 | Universitas Padjadjaran | N/A |
| Unknown | Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis NCT02464683 | Instituto Nacional de Enfermedades Respiratorias | Phase 4 |
| Completed | Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indone NCT02554318 | University of Giessen | N/A |
| Completed | Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers NCT01927159 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Completed | Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight D NCT02558842 | Hospital de Clinicas de Porto Alegre | N/A |
| Completed | Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis NCT02467608 | Orient Pharma Co., Ltd. | Phase 2 / Phase 3 |
| Completed | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa NCT01691534 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers NCT01599897 | Access to Advanced Health Institute (AAHI) | Phase 1 |
| Completed | Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients W NCT01498419 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Evaluation of PTB Screening in ANC in Lusaka, Zambia NCT02053129 | University of North Carolina, Chapel Hill | N/A |
| Completed | Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis NCT02313610 | Shanghai University of Traditional Chinese Medicine | Phase 2 |
| Completed | Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB) NCT01580007 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 2 |
| Completed | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) NCT01215851 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001) NCT01215110 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Latency in Pulmonary Tuberculosis NCT01154959 | Tuberculosis Research Centre, India | Phase 3 |
| Completed | A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary T NCT00366470 | Peter Daley | Phase 3 |
| Unknown | Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease NCT01503099 | Lovisenberg Diakonale Hospital | — |
| Completed | Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010) NCT00944021 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Induced Sputum Versus Bronchoscopy in Smear Negative Pulmonary Tuberculosis NCT01011543 | Centre Hospitalier Universitaire Saint Pierre | N/A |
| Completed | Tuberculosis Volatile Organic Compounds NCT01379066 | Landon Pediatric Foundation | — |
| Unknown | Pharmacokinetic Study for Anti-tuberculosis Drugs NCT00948077 | Taipei Medical University WanFang Hospital | N/A |
| Unknown | Prevalence and Clinical Significance of Co-infection of Mycoplasma Pneumoniae in Patients With Pulmonary Tuber NCT00926601 | Seoul National University Hospital | — |
| Completed | Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament NCT01002170 | Taipei Medical University WanFang Hospital | — |
| Completed | Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in NCT01618422 | Chinese University of Hong Kong | N/A |
| Completed | TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment NCT00694629 | Centers for Disease Control and Prevention | Phase 2 |
| Completed | Linezolid to Treat Extensively-Drug Resistant Tuberculosis NCT00727844 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Terminated | Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2) NCT00571753 | University of Cologne | Phase 3 |
| Unknown | Efficacy of Oral Zinc Administration as an Adjunct Therapy in New Pulmonary Tuberculosis (Category I) Patients NCT00698386 | Ministry of Science and Technology, India | Phase 3 |
| Completed | Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis NCT00864383 | Global Alliance for TB Drug Development | Phase 3 |
| Completed | PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis NCT00567840 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis NCT00401271 | Otsuka Frankfurt Research Institute GmbH | Phase 2 |
| Completed | Improving Community Based Tuberculosis Care in Ethiopia NCT00803322 | University of Bergen | — |
| Completed | Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Re NCT00772408 | Chang Gung Memorial Hospital | — |
| Completed | Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Fact NCT00834353 | Maulana Azad Medical College | — |
| Withdrawn | Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment NCT00517231 | UPECLIN HC FM Botucatu Unesp | — |
| Completed | Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT) NCT00298870 | Osaka University | Phase 4 |
| Completed | Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis NCT01242592 | NMP Medical Research Institute | Phase 2 |
| Completed | Vitamin A Therapy for Tuberculosis NCT00057434 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis NCT00023335 | Centers for Disease Control and Prevention | Phase 3 |
| Completed | Interferon Gamma for Drug Resistant Tuberculosis NCT00001407 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |